Loading...

Member Profile

Home / Members

SynCore Biotechnology Co., Ltd.




Chairman
  • Chih Wen Lee
Date Established
  • 2008/06/26
TWSE Stock ID
  • 4192
Market Valuation
  • USD  70,000,000.0
Phone Number
  • +886-2-2760-0826
Address
  • 4F, No.69, DongXing Rd., XinYi Dist., Taipei City 110, Taiwan
Website Theraputic Fields
  • Dermatology
  • Oncology
  • Ophthalmology
Product Classification
  • Small Molecule Drugs
  • Botanical Drugs
  • 505(b)(2)
  • Technology Platform
Awards
  1. 2012 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Awards
  2. 2013 10th National Innovation Award
  3. 2014 Taiwan Bio Industry Organization Award: Emerging Company of The Year
  4. 2018 Taiwan Bio Industry Organization Award: Innovation of The Year
  5. 2018 15th National Innovation Award
  6. 2019 Clinical & Research Excellence Awards 2019 Finalist: Excellence in Rare Disease Drug Development
  7. 2020 17th Anniversary of 2020 Taipei Biotech Awards: Innovation Award > Special Mention Award
  8. 2021 XV InternationalWarsaw Invention Show- Gold awards
  9. 2021 America’s Science & Invention Expo- Gold awards
  10. 2021 Taipei Biotechnology Award-Innovative Technology Award-Excellence Award
Top Products
  1. The manufacturing and deliver rights of Veregen ®
  2. EpiCam Hand-Held Fundus Camera
  3. SynCoreBio CysLute EX Capsules
    杏國.png

SynCore Biotechnology Co., Ltd. (“SynCoreBio”) is a biopharmaceutial company focusing on creating values of new drug by R&D and integration of technology resources. SynCore was established in 2008 and cofounded by Sinphar Group and National Health Research Institute (NHRI). SynCore inherited Sinphar’s experiences which have been accumulated for more than 30 years in R&D, manufacturing, and international marketing. Such experiences enables SynCore to build up the comprehensive pipeline portfolio for new drug development to fulfill domestic and international market needs and to consolidate the future development.

SynCore utilizes and in-licenses the unique technologies from all over the world to develop new drugs with great marketing potential. By professional and expeditious project management, SynCore accumulates intangible assets to promote its marketing values. SynCore keeps looking for international partners actively and guarantee stable and long-term profits through strategic alliance to enrich sustainable operating energy.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2017 SynCoreBio receives investigational new drug (IND) clearance of SB05 (EndoTAG®-1) by the Taiwan Food and Drug Administration (TFDA) to conduct a Phase III clinical trial for the treatment of metastatic adenocarcinoma of the Pancreas.
   2018 SynCoreBio signs agreement with British Company Epipole to distribute ophthalmic diagnosis fundus cameras in Taiwan.
   2019 SynCoreBio is approved by the National Medical Product Administration (NMPA) of China to conduct Phase III Clinical trial of first-line treatment for pancreatic cancer in China.
   2021 SynCoreBio SB05 EndoTAG-1 receives the EU and CN invention patent certification.
   2021 SynCore Biotechnology Announces Final Analysis Results for Novel Pancreatic Cancer Asset, SB05PC (EndoTAG®-1).
   2022 SynCore Bio Doses First Patient In First-line Phase III Trial for SB05 (EndoTAG®-1)Pancreatic Cancer in China.
   2022 SynCore SB05PC abstract accepted at ESMO Asia Congress 2022
   2022 SynCore presented poster at ESMO Asia Congress 2022